Saturday 17 October 2026
Export TLSI’s income statement to Excel — free account
TriSalus Life Sciences, Inc.
TLSI Healthcare Medical Devices
TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024. In the quarter to June 2026, revenue grew 1.73%, EPS grew 40.7%, free cash flow fell 41.3% and total debt rose 2.45%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
3.63
0.27
−6.92%
Follow TLSI
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 9.45 | 8.99 | 3.32 | 3.50 | 3.42 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 11.18 | 10.68 | 16.24 | 10.42 | 7.95 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 3 | 112 | 110 | 102 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 4.13 | 0.17 | 0.27 | 0.44 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 12 | 19 | 29 | 45 | ||||
| Gross margin, % | — | — | — | — | — | — | 81.79 | 85.93 | 86.06 | 84.57 | |||||
| EBT | — | — | — | — | (1) | 5 | (47) | (59) | (30) | (39) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | (380.53) | (320.64) | (102.07) | (86.86) | |||||
| Net income | — | 0 | — | — | (1) | 5 | (47) | (59) | (30) | (39) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 1 | 1 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 39.99 | 1.97 | 1.16 | 1.19 | ||||
| Earnings | — | — | — | — | (0.11) | 0.76 | (152.22) | (6.73) | (1.31) | (1.84) | |||||
| Cash flow | — | — | — | — | (0.11) | (0.28) | (104.24) | (5.38) | (1.61) | (0.48) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | (2.54) | (0.12) | (0.01) | (0.02) | |||||
| Free cash flow | — | — | — | — | (0.11) | (0.28) | (106.77) | (5.50) | (1.63) | (0.50) | |||||
| Book value | — | — | — | — | (3.40) | (2.67) | (568.81) | (2.88) | (1.02) | (0.89) | |||||
| Shares, m | — | — | — | — | 6 | 6 | 0 | 9 | 25 | 38 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | 4.19 | 4.31 | 5.86 | |||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 3.64 | 4.78 | 6.14 | |||||
| EV/FCF | — | — | — | — | — | — | 0.12 | (1.30) | (3.36) | (14.16) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (1) | (2) | (32) | (51) | (41) | (18) | ||||
| Capex | — | — | — | — | — | — | (1) | (1) | 0 | (1) | |||||
| Free cash flow | — | — | — | — | (1) | (2) | (33) | (52) | (41) | (19) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 2 | (1) | (15) | 6 | 10 | 21 | ||||
| Total debt | — | — | — | — | — | 1 | 1 | — | 22 | 33 | |||||
| Net debt | — | — | — | — | (1) | 0 | (8) | (12) | 14 | 13 | |||||
| Shareholders’ equity | — | — | — | — | (21) | (17) | (176) | (27) | (26) | (34) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (0.56) | 1.90 | (36.71) | (273.01) | (136.85) | (235.03) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | (0.60) | (24.96) | 51.82 | 62.54 | 125.50 | 233.25 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
TriSalus Life Sciences, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CLPT ClearPoint Neuro, Inc. | $294.1M | — (loss-making) | — (loss-making) | +18.07% (above 0%: growing) | n/m | −173.51% (below 0%: shrinking) | 61.67% | (94.15%) | Compare |
| QSI Quantum-Si Incorporated | $286.7M | — (loss-making) | — (loss-making) | −41.79% (below 0%: shrinking) | n/m | +9.75% (above 0%: growing) | 50.00% | (7,450.29%) | Compare |
| INFU InfuSystems Holdings, Inc. | $277.2M | 31.7× | 21.7× | +2.59% (above 0%: growing) | +33.33% (above 0%: growing) | −66.54% (below 0%: shrinking) | 57.98% | 11.24% | Compare |
| TMCI Treace Medical Concepts, Inc. | $267.9M | — (loss-making) | — (loss-making) | −4.24% (below 0%: shrinking) | n/m | +11.74% (above 0%: growing) | 78.47% | (32.96%) | Compare |
| CATX Perspective Therapeutics, Inc. | $267.1M | — (loss-making) | — (loss-making) | −72.07% (below 0%: shrinking) | n/m | −66.09% (below 0%: shrinking) | 100.00% | (36,120.99%) | Compare |
| LAB Standard BioTools Inc. | $258.5M | 2.9× | — (loss-making) | −7.62% (below 0%: shrinking) | n/m | +52.76% (above 0%: growing) | 52.40% | (126.28%) | Compare |
| TLSI TriSalus Life Sciences, Inc. | $240.1M | — (loss-making) | — (loss-making) | +1.73% (above 0%: growing) | n/m | −41.29% (below 0%: shrinking) | 86.78% | (86.03%) | |
| ELMD Electromed, Inc. | $232.3M | 20.0× | 25.5× | +11.64% (above 0%: growing) | +57.69% (above 0%: growing) | −25.15% (below 0%: shrinking) | 78.71% | 19.70% | Compare |
| PROF Profound Medical | $230.5M | — (loss-making) | — (loss-making) | +12.30% (above 0%: growing) | n/m | +17.51% (above 0%: growing) | 78.41% | (445.67%) | Compare |
| Median of peers | $267.5M | 20.0× | — | −0.82% | — | −7.70% | 70.04% | (110.21%) |
TriSalus Life Sciences, Inc. (TLSI) key facts
- Strength: TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024.
- TriSalus Life Sciences, Inc. (TLSI) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TLSI traded at $3.63, a market capitalization of $240.1 million.
- Return on equity was 233.3% and debt-to-equity 5.05.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −11.34 (distress zone) for fiscal 2025.